GPN Vaccines closes A$7 million Series A2 round oversubscribed with Forepont Capital Partners becoming a significant investor
GPN Vaccines is a biotechnology company developing a vaccine against Streptococcus pneumoniae (the pneumococcus) – the world’s foremost bacterial pathogen. S. pneumoniae is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections). Each year it causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now 100 different serotypes of Streptococcus pneumoniae and the best vaccine currently on the market only protects against 13 of them. Our vaccine, termed Gamma-PNTM, is being developed to protect children and adults against all S. pneumoniae strains, regardless of strain serotype.